Mixed Hypertrophic and Dilated Phenotype of Cardiomyopathy in a Patient With Homozygous In-Frame Deletion in the MyBPC3 Gene Treated as Myocarditis for a Long Time

Hypertrophic cardiomyopathy (HCM) is the most common inherited disease, with a prevalence of 1:200 worldwide. The cause of HCM usually presents with an autosomal dominant mutation in the genes encoding one of more than 20 sarcomeric proteins, incomplete penetrance, and variable expressivity. HCM cla...

Full description

Saved in:
Bibliographic Details
Main Authors: Olga Blagova (Author), Indira Alieva (Author), Eugenia Kogan (Author), Alexander Zaytsev (Author), Vsevolod Sedov (Author), S. Chernyavskiy (Author), Yulia Surikova (Author), Ilya Kotov (Author), Elena V. Zaklyazminskaya (Author)
Format: Book
Published: Frontiers Media S.A., 2020-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ca6f0dd9e93c4460a8e8a844d864a906
042 |a dc 
100 1 0 |a Olga Blagova  |e author 
700 1 0 |a Indira Alieva  |e author 
700 1 0 |a Eugenia Kogan  |e author 
700 1 0 |a Alexander Zaytsev  |e author 
700 1 0 |a Vsevolod Sedov  |e author 
700 1 0 |a S. Chernyavskiy  |e author 
700 1 0 |a Yulia Surikova  |e author 
700 1 0 |a Ilya Kotov  |e author 
700 1 0 |a Elena V. Zaklyazminskaya  |e author 
245 0 0 |a Mixed Hypertrophic and Dilated Phenotype of Cardiomyopathy in a Patient With Homozygous In-Frame Deletion in the MyBPC3 Gene Treated as Myocarditis for a Long Time 
260 |b Frontiers Media S.A.,   |c 2020-09-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2020.579450 
520 |a Hypertrophic cardiomyopathy (HCM) is the most common inherited disease, with a prevalence of 1:200 worldwide. The cause of HCM usually presents with an autosomal dominant mutation in the genes encoding one of more than 20 sarcomeric proteins, incomplete penetrance, and variable expressivity. HCM classically manifests as an unexplained thickness of the interventricular septum (IVS) and left ventricular (LV) walls, with or without the obstruction of the LV outflow tract (LVOT), and variable cardiac arrhythmias. Here, we present a rare case of mixed cardiomyopathy (cardiac hypertrophy and dilation) and erythrocytosis in a young patient. A 27-year-old man was admitted to the clinic due to biventricular heart failure (HF) NYHA class III. Personal medical records included a diagnosis of dilated cardiomyopathy (DCM) since the age of 4 years and were, at the time, considered an outcome of myocarditis. Severe respiratory infection led to circulatory decompensation and acute femoral thrombosis. The combination of non-obstructive LV hypertrophy (LV walls up to 15 mm), LV dilatation, decreased contractility (LV EF 24%), and LV apical thrombosis were seen. Cardiac MRI showed a complex pattern of late gadolinium enhancement (LGE). Endomyocardial biopsy (EMB) revealed primary cardiomyopathy with intravascular coagulation and an inflammatory response. No viral genome was detected in the plasma or EMB samples. Whole exome sequencing (WES) revealed a homozygous in-frame deletion p.2711_2737del in the MyBPC3 gene. The clinically unaffected mother was a heterozygous carrier of this deletion, and the father was unavailable for clinical and genetic testing. Essential erythrocytosis remains unexplained. No significant improvement was achieved by conventional treatment, including prednisolone 40 mg therapy. ICD was implanted due to sustained VT and high risk of SCD. Orthotopic heart transplantation (HTx) was considered optimal. Early manifestation combined hypertrophic and dilated phenotype, and progression may reflect a complex genotype with more than one pathogenic allele and/or a combination of genetic diseases in one patient. 
546 |a EN 
690 |a hypertrophic cardiomyopathy 
690 |a dilated cardiomyopathy 
690 |a MyBPC3 gene 
690 |a heart failure progression 
690 |a bi-allelic mutations 
690 |a myocarditis 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 11 (2020) 
787 0 |n https://www.frontiersin.org/article/10.3389/fphar.2020.579450/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/ca6f0dd9e93c4460a8e8a844d864a906  |z Connect to this object online.